

# SEQUENCE LISTING

<110> LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES  
BIOTECHNOLOGIES (LFB)

<110> INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE  
(INSERM)

<120> THERAPEUTIC PRODUCTS WITH ENHANCED ABILITY TO IMMUNOMODULATE CELL  
FUNCTIONS

<130> D21018

<150> EP 03/290 834

<151> 2003-04-03

<160> 6

<170> PatentIn version 3.2

<210> 1

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 1  
gcagctcccc caaaggctgt g 21

<210> 2

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 2  
ttggacagtg atggtcacag g 21

<210> 3

<211> 33

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 3  
tggatgaatt ccctattaag tgatggtgat gtt 33

<210> 4

<211> 23

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 4

atcggatccc gactgaagat etc

23

<210> 5

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB1/LFB2 antibody.

<400> 5

gcctccacca	agggcccatc	ggtcttcccc	ctggcaccct	cctccaagag	cacctctggg	60
ggcacagcgg	ccctgggctg	cctgggtcaag	gactacttcc	ccgaaccggt	gacgggtgtcg	120
tggaaactcag	gcgccctgac	cagcggcgctg	cacaccttcc	cggtctgtcct	acagtcctca	180
ggactctact	ccctcagcag	cgtgggtgacc	gtgccctcca	gcagcttggg	caccagacc	240
tacatctgca	acgtgaatca	caagcccagc	aacaccaagg	tggacaagaa	agttgagccc	300
aaatcttgtg	acaaaactca	cacatgcccc	ccgtgcccag	cacctgaact	cctgggggga	360
ccgtcagtcct	tcctcttccc	cccaaaaccc	aaggacaccc	tcctgatctc	ccggacccct	420
gaggtcacat	gcgtgggtgt	ggacgtgagc	cacgaagacc	ctgaggtcaa	gttcaactgg	480
tacgtggacg	gcgtggaggt	gcataatgcc	aagacaaaagc	cgcgaggaga	gcagtacaac	540
agcacgtacc	gtgtgggtcag	cgctctcacc	gtcctgcacc	aggactgggt	gaatggcaag	600
gagtacaagt	gcaaggtctc	caacaaagcc	ctcccagccc	ccatcgagaa	aacctctctc	660
aaagccaaag	ggcagccccg	agaaccacag	gtgtacaccc	tgccccatc	ccgggatgag	720
ctgaccaaga	accaggtcag	cctgacctgc	ctgggtcaaag	gcttctatcc	cagcgacatc	780
gccgtggagt	gggagagcaa	tgggcagccg	gagaacaact	acaagaccac	gcctcccgtg	840
ctggactccg	acggctcctt	cttctcttac	agcaagctca	ccgtggacaa	gagcaggtgg	900
cagcagggga	acgtcttctc	atgctccgtg	atgcatgagg	ctctgcacaa	ccactacacg	960
cagaagagcc	tctccctgtc	tccgggtaaa				990

<210> 6

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB3 antibody.

<400> 6

gcctccacca	agggcccatc	ggtcttcccc	ctggcaccct	cctccaagag	cacctctggg	60
ggcacagcgg	ccctgggctg	cctgggtcaag	gactacttcc	ccgaaccggt	gacgggtgtcg	120
tggaaactcag	gcgccctgac	cagcggcgctg	cacaccttcc	cggtctgtcct	acagtcctca	180
ggactctact	ccctcagcag	cgtgggtgacc	gtgccctcca	gcagcttggg	caccagacc	240
tacatctgca	acgtgaatca	caagcccagc	aacaccaagg	tggacaagag	agttgagccc	300
aaatcttgtg	acaaaactca	cacatgcccc	ccgtgcccag	cacctgaact	cctgggggga	360
ccgtcagtcct	tcctcttccc	cccaaaaccc	aaggacaccc	tcctgatctc	ccggacccct	420
gaggtcacat	gcgtgggtgt	ggacgtgagc	cacgaagacc	ctgaggtcaa	gttcaactgg	480
tacgtggacg	gcgtggaggt	gcataatgcc	aagacaaaagc	cgcgaggaga	gcagtacaac	540
agcacgtacc	gtgtgggtcag	cgctctcacc	gtcctgcacc	aggactgggt	gaatggcaag	600
gagtacaagt	gcaaggtctc	caacaaagcc	ctcccagccc	ccatcgagaa	aacctctctc	660
aaagccaaag	ggcagccccg	agaaccacag	gtgtacaccc	tgccccatc	ccgggaggag	720
atgaccaaga	accaggtcag	cctgacctgc	ctgggtcaaag	gcttctatcc	cagcgacatc	780

gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 840  
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg 900  
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960  
cagaagagcc tctccctgtc cccgggtaaa 990